CVE:ACST Acasti Pharma (ACST) Stock Price, News & Analysis → Buy Friday, Sell Monday, No Exceptions (From DTI) (Ad) Free ACST Stock Alerts C$0.58 +0.01 (+1.75%) (As of 03/27/2023) Add Compare Share Share Today's RangeC$0.56▼C$0.5850-Day RangeC$0.58▼C$0.5852-Week RangeC$0.47▼C$1.66Volume2,450 shsAverage Volume6,576 shsMarket CapitalizationC$25.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Acasti Pharma alerts: Email Address Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Acasti Pharma Stock (CVE:ACST)Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.Read More ACST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACST Stock News HeadlinesMarch 14, 2024 | edition.cnn.comAcasti Pharma Inc. Class AFebruary 25, 2024 | msn.comAcasti Pharma (ACST) Price Target Increased by 200.00% to 6.12March 28, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.February 12, 2024 | finance.yahoo.comAcasti Announces Third Fiscal Quarter 2024 Financial Results and Business HighlightsDecember 25, 2023 | finance.yahoo.comWill Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?November 14, 2023 | investing.comAcasti Pharma (ACST) Earnings Dates & ReportsNovember 11, 2023 | morningstar.comAcasti Pharma Inc Class A ACSTSeptember 26, 2023 | benzinga.comWhy Acasti Pharma (ACST) Stock Is Exploding HigherMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…September 6, 2023 | technews.tmcnet.comAcasti to Participate in the H.C. Wainwright Global Investment ConferenceAugust 11, 2023 | finanznachrichten.deAcasti Pharma, Inc.: Acasti Announces First Quarter 2024 Financial Results and Business HighlightsJune 23, 2023 | finanznachrichten.deAcasti Pharma Inc.: Acasti Pharma Reports Fiscal Year 2023 Operational ResultsJune 23, 2023 | finance.yahoo.comAcasti Pharma Reports Fiscal Year 2023 Operational ResultsJune 22, 2023 | finance.yahoo.comAcasti Announces Appointment of New Scientific Advisory Board MembersJune 20, 2023 | sg.finance.yahoo.comACST - Acasti Pharma Inc.April 7, 2023 | theglobeandmail.comClosing Bell: Acasti Pharma Inc up on Monday (ACST)April 4, 2023 | seekingalpha.comAcasti Pharma announces CEO transitionMarch 16, 2023 | morningstar.comAcasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange | MorningstarMarch 8, 2023 | finance.yahoo.comAcasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare ConferenceMarch 4, 2023 | finance.yahoo.comWe're Hopeful That Acasti Pharma (CVE:ACST) Will Use Its Cash WiselyMarch 1, 2023 | finance.yahoo.comAcasti Pharma Recognizes Rare Disease DayFebruary 28, 2023 | msn.comHas Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?January 13, 2023 | benzinga.comAcasti Pharma to Present at Sidoti Virtual Investor Conference on January 18November 15, 2022 | seekingalpha.comAcasti Pharma Inc. (ACST) Q2 2023 Earnings Call TranscriptNovember 9, 2022 | it.tmcnet.comAcasti Pharma to Present at Q4 Investor SummitNovember 8, 2022 | tmcnet.comAcasti Pharma to Report Second Quarter 2023 FinancialSeptember 17, 2022 | theglobeandmail.comAcasti Pharma: Top 10 Undervalued Biotechnology Industry Sector Stocks on TSX Venture Exchange (ACST)See More Headlines Receive ACST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:ACST Previous SymbolCVE:APO CUSIPN/A CIKN/A Webwww.acastipharma.com Phone+1-450-6864555FaxN/AEmployees32Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-17,250,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-16.60% Return on Assets-8.25% Debt Debt-to-Equity Ratio0.52 Current Ratio9.74 Quick Ratio9.41 Sales & Book Value Annual SalesC$115,000.00 Price / Sales224.99 Cash FlowC$0.93 per share Price / Cash Flow0.63 Book ValueC$2.17 per share Price / Book0.27Miscellaneous Outstanding Shares44,610,000Free FloatN/AMarket CapC$25.87 million OptionableNot Optionable Beta1.22 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMs. Janelle D'Alvise (Age 68)Pres, CEO, Corp. Sec. & Director Comp: $620.16kDr. Pierre Lemieux M.D. (Age 58)Ph.D., Co-Founder, COO & Chief Scientific Officer Comp: $398.75kMr. Brian D. Ford CPA (Age 64)CA, Chief Financial Officer Comp: $340.84kDr. George Kottayil (Age 60)Chief Operating Officer of US Comp: $160.16kMr. Prashant KohliChief Commercial OfficerDr. Yves Lachance Ph.D.VP of Quality & ComplianceMs. Christine PelletierSr. Director of HRMore ExecutivesKey CompetitorsCovalon TechnologiesCVE:COVAntibe TherapeuticsTSE:ATELiberty BiopharmaCVE:LTYDevonian Health GroupCVE:GSDAptose BiosciencesTSE:APSView All Competitors ACST Stock Analysis - Frequently Asked Questions How have ACST shares performed in 2024? Acasti Pharma's stock was trading at C$0.58 on January 1st, 2024. Since then, ACST shares have increased by 0.0% and is now trading at C$0.58. View the best growth stocks for 2024 here. What other stocks do shareholders of Acasti Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), Aurora Cannabis (ACB), SCYNEXIS (SCYX), Block (SQ), Nokia Oyj (NOK), Axsome Therapeutics (AXSM), Blink Charging (BLNK), Inovio Pharmaceuticals (INO), Okta (OKTA) and Tesla (TSLA). How do I buy shares of Acasti Pharma? Shares of ACST stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:ACST) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acasti Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.